Visual Outcome and Fluid Changes Between Eyes With Polypoidal Choroidal Vasculopathy Receiving Biosimilar CKD-701 or Reference Ranibizumab Therapy: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial

CONCLUSION: Biosimilar CKD-701 monotherapy resulted in comparable visual and anatomical changes to those achieved with reference ranibizumab in PCV eyes.PMID:38450631 | DOI:10.1080/02713683.2024.2323506

Source: Current Eye Research - March 7, 2024 Category: Opthalmology Authors: Ki Tae Nam Cheolmin Yun Young Joo Lee Mihyun Choi Dongwan Kang Jaeryung Oh Source Type: research